This startup integrates artificial intelligence into healthcare operations to lower costs and enhance patient outcomes through data-driven decision-making. By applying insights from PhD research, the company optimizes resource allocation in medical facilities, improving efficiency and care delivery.
Funding
Funding not disclosed
Founders
Product
Problem
Detecting and diagnosing brain diseases like Alzheimer's and dementia early is challenging due to limited options and the lack of built-in software in existing PET/MR/CT scanners to comprehensively analyze brain biology and identify Network Diaschisis. This results in delayed diagnoses and fewer opportunities to slow disease progression.
Solution
Segtnan AI offers a globally accessible, AI-powered system that analyzes FDG-PET scans to provide a comprehensive assessment of brain functionality. The system integrates risk assessment for various biological brain diseases and learns from each analyzed image. The AI maps the brain's biology in 3D, providing a "Brain Score" biomarker that quantifies overall brain functionality and aids in identifying Network Diaschisis. This serverless online platform can be integrated into any hospital's existing infrastructure to enhance diagnostic accuracy and support clinical decision-making.
Target Audience
The primary target audience includes hospitals, research institutions, and healthcare providers seeking to improve the early detection and diagnosis of neurological disorders using advanced brain scan analysis.
Features
- AI-powered analysis of FDG-PET scans, mapping the brain's biology in 3D
- Segtnan Brain Score: a biomarker quantifying overall brain functionality
- Identification of Network Diaschisis
- Serverless online platform for seamless integration with existing hospital systems
- AI model that learns and improves with each analyzed image
- Validated on data from thousands of patients, demonstrating high sensitivity and specificity